• Ascentage Pharma will hold its annual general meeting in Suzhou, China on May 20, 2026.
• Shareholders will vote on proposed restricted share unit grants to Dajun Yang and Yifan Zhai under 2022 RSU Scheme, totaling 804,880 RSUs.
• Meeting agenda also includes proposed post-IPO share option grants to Yang and Zhai, totaling 616,556 options with exercise prices of HK$ 63.35 or HK$ 51.58 per share depending on grant date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260430-12141008), on April 30, 2026, and is solely responsible for the information contained therein.